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Induction of the Neurokinin 1 Receptor by TNF in
Endometriotic Tissue Provides the Potential for
Neurogenic Control Over Endometriotic Lesion
Growth
Brett D. McKinnon, Jakob Evers, Nick A. Bersinger, and Michael D. Mueller
Department of Obstetrics and Gynaecology, Inselspital, University of Berne, Berne, CH-3010, Switzerland
Context: Endometriosis is characterized by the growth of ectopic endometrial tissue. Nerve fibers
are frequently associated with ectopic lesions, and neurogenic inflammation may play a role in
endometriosis.
Objective: The purpose of this study was to determine the presence of tachykinin receptors in
endometriotic lesions and the role of TNF on their expression.
Design: This study was an assessment of matching eutopic and ectopic endometrial tissue and
peritoneal fluid from patients with endometriosis and an in vitro analysis of primary endometrial
cells.
Setting: The setting was a university hospital.
Patients: Participants were premenopausal women undergoing laparoscopy.
Interventions: Endometriotic lesions were removed surgically.
Main Outcome Measures: Tachykinin mRNA (TACR1/2) and protein (neurokinin 1 receptor [NK1R])
expression in both eutopic and ectopic endometrial tissue from patients with endometriosis and the
correlation to peritoneal fluid TNFweremeasured. Primary endometrial epithelial and stromal cells
were assessed in vitro to determine the induction of TACR1/2 and NK1R expression after TNF treat-
ment. Cell viability of endometrial stromal cells after substance P exposure was also assessed.
Results: Expression of both TACR1 and TACR2 mRNA was significantly higher in the ectopic than
in the eutopic tissue. Both TACR1mRNA and NK1R protein expression was significantly correlated
withperitoneal fluidTNF, and invitro studies confirmedthatTNF treatment inducedbothTACR1
mRNA and NK1R protein expression in endometrial stromal cells. In endometrial stromal cells,
substance P treatment enhanced cell viability, which was inhibited by a specific NK1R antagonist.
Conclusions: NK1R expression is induced in ectopic endometrial tissue by peritoneal TNF. Induc-
tion of NK1R expression may permit endometriotic lesion maintenance via exposure to substance
P. (J Clin Endocrinol Metab 98: 2469–2477, 2013)
Endometriosis is characterized by the growth of endo-metrial epithelial and stromal cells outside theuterine
cavity. The growth of ectopic endometrial lesions can re-
sult in severe dysmenorrhea, chronic pelvic pain, and re-
duced fecundity. It is a prevalent disease affecting approx-
imately 10%ofwomenduring their reproductive years (1)
and represents a significant reduction in the quality of life
and a burden on health care systems (2). The mechanisms
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that underlie both the pathophysiology of growth of le-
sions and the pain they cause are unknown, although an
aberrant immune response after retrograde menstruation
plays an important role (3).
Sensory nerve fibers can innervate endometriotic le-
sions, and thus neurogenic inflammation may have a role
in the pathogenesis of endometriosis. Although early stud-
ies found no difference in the number of nerve fibers be-
tween women with and without endometriotic lesions in
either the peritoneal wall (4, 5) or the rectovaginal septum
(RVS) region (6), there was a significant difference re-
ported in the degree of intraneurial and perineurial inva-
sion of RVS lesions (6) and an increased density of nerve
fibers proximal to endometriotic lesions on the peritoneal
wall (7), a high proportion of which were confirmed as
sensory nerve fibers (5, 7). Sensory nerve fibers transmit
afferent pain signals and can also elicit a local response via
neurogenic inflammation. Substance P (SP), a member of
the tachykinin family, is one of the strongest mediators of
neurogenic inflammation (8, 9) and is secreted by afferent
sensory neurons (10). It has previously been detected in
sensory nerve fibers close to endometriotic lesions (5, 7)
and is present in peritoneal fluid (11).
SP can activate neurogenic inflammation by binding to
the neurokinin 1 receptor (NK1R). NK1R is up-regulated
by inflammation (12) and is involved in a number of in-
flammatory conditions (13, 14). The presence ofNK1Ror
the gene that encodes it, TACR1, has not been reported
previously in endometriotic lesions despite the importance
of inflammation to the progression of the disease.We pro-
posed that endometriotic lesions express NK1R, that this
expression is related to the inflammatory microenviron-
ment, and that activation of NK1R will affect endometri-
otic lesionviability.We therefore examined the expression
of NK1R in both eutopic and ectopic endometrial tissue
and determined whether this expression was related to
inflammatory cytokines present in the peritoneal fluid. In
additionwe also assessed the viability of endometrial cells
in vitro after exposure to SP.
Materials and Methods
Sample collection and patient data
Institutional review board approval was obtained from the
ethics committee before commencement of the study. During
laparoscopic surgery to investigate pelvic pain or infertility, any
endometriotic lesions identified were removed, their location
was noted (peritoneum, ovary, or RVS), and they were stored in
either dimethyl sulfoxide (Sigma, Buchs, Switzerland) or RNAl-
ater (Invitrogen Life Technologies, Zug, Switzerland) or frozen
in liquid nitrogen. Peritoneal fluid was collected from the pouch
ofDouglas (cul-de-sac), clarified by centrifugation, and stored at
80°C. Eutopic endometrial biopsy samples were obtained us-
ing a soft curette (Pipelle de Cornier, Laboratoire C.C.D., Paris,
France) and treated the same way as the lesions. Exclusion cri-
teria for the study included prior or current infections, liver dys-
function, or the use of GnRH analogs within the past 3 months.
All laparoscopies were performed during the proliferative phase
of the menstrual cycle.
During the study period, 35 distinct endometriotic lesions
were collectedwith amatching eutopic endometrial biopsy sam-
ple during the same operation. Themajor indications for surgery
included dysmenorrhea (19 samples), pelvic pain (9 samples),
dyspareunia (2 samples), and infertility (5 samples). Of these 35
samples, 21 were stored in RNAlater and 14 were stored fresh-
frozen. The ectopic samples stored in RNAlater included 8 le-
sions from the peritoneum, 9 lesions from the ovaries, and 4
lesions from the RVS. The fresh-frozen ectopic samples included
3 lesions from the peritoneum, 7 lesions from the ovaries, and 4
lesions from the RVS.
Isolation and culture of endometrial epithelial and
stromal cells
Primary endometrial epithelial cells (EECs) and endometrial
stromal cells (ESCs) were isolated from endometrial biopsy sam-
ples collected during the proliferative phase and stored in di-
methyl sulfoxide. Separation was performed via collagenase di-
gestion and size exclusion membranes as described previously
(15). A total of 6 primary cell isolations were performed, and
sufficient EECs and ESCs were isolated in 4 and 6 preparations,
respectively. All preparations were fromwomenwith confirmed
endometriosis, and no hormonal therapy for at least 3 months
before surgery.
Isolated EECs and ESCsweremaintained inDulbecco’smod-
ified Eagle’s medium (Invitrogen Life Technologies) supple-
mentedwith 10%fetal calf serum (InvitrogenLifeTechnologies)
and 1% antibiotic/antimyotic (Invitrogen Life Technologies).
Cells were seeded into 6-well (ESCs) or 24well plates (EECs) for
subsequent RNA collection or onto sterile coverslips for immu-
nofluorescence. Before treatments, cells were serum-starved
overnight (Dulbecco’s modified Eagle’s mediumwith 0.5% fetal
calf serum) and treatment was with either 0, 10, or 100 ng/mL
TNF for 6 hours.
Determination of gene expression in eutopic and
ectopic tissue
Approximately 30 mg of tissue from both the eutopic endo-
metrial biopsy samples and ectopic endometriotic lesions was
excised and homogenized in FastPrep 120 tissue homogenizer
(30 seconds at 4.0 m/s) in cell lysis buffer (Qiagen, Düsseldorf,
Germany). The remainingRNA isolationwasperformedwith an
RNAeasy mini kit (Qiagen) and TURBO DNase (Ambion Life
Technologies, Zug, Switzerland) for genomic DNase digestion.
Onemicrogramof total RNAwas reverse transcribed in a 25-L
reaction withMoloney murine leukemia virus reverse transcrip-
tase (Promega, Dübendorf, Switzerland) and random primers.
The resulting cDNA was diluted 1:20, and the absence of
genomic DNA was confirmed with a reverse transcriptase
control.
Quantitative real-time PCR was performed with TaqMan
Fast AdvancedMasterMix (Invitrogen Life Technologies) and a
Rotor-Gene RG 2000 (Corbett Research, Sydney, NSW, Aus-
tralia), under the following conditions: 50°C for 2 minutes and
then 95°C for 20 seconds, followed by 40 cycles of 95°C for 1
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second and 60°C for 20 seconds. Product size was confirmed on
a 4% agarose gel.
A TaqMan gene expression assay was used for the genes of
interest: TACR1 (NM_001058; Hs00185530_m1), TACR2
(NM_001057; Hs00169052_m1), and TACR3 (NM_001050.1;
Hs00357277_m1)andthereferencegenesGAPDH (NM_002046;
Hs00266705_g1), ACTB (NM_001101; Hs01060665_g1),
YWHAZ (NM_003406; Hs03044281_g1), and RPL13A
(NM_012423; Hs04194366_g1) (Invitrogen Life Technologies).
The number of andmost stable reference genes were selected via
the geNORM software program, which is part of the qBASE
software suite (Biogazelle, Zwijinaarde, Gent, Belgium), and a
geometric mean of all 4 reference genes was used to normalize
TACR1/2 expression for each tissue type (16). The reaction ef-
ficiency of each assay was determined via linear regression (17),
and the fold change was calculated with qBASEplus software.
Determination of NK1R protein expression in
ectopic endometrial tissue
Whole cell extracts were prepared from fresh-frozen ectopic
endometrial tissue by homogenization with the FastPrep 120
tissue homogenizer (30 seconds at 4.0 m/s) in radioimmunopre-
cipitation assay buffer (50mMTris  Cl, pH 7.4, 150mMNaCl,
1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate,
0.1%sodiumdodecyl sulfate, and1%protease andphosphatase
inhibitor cocktail [Cell Signaling Technology, Danvers, Massa-
chusetts]). Protein concentrations were determined by the bicin-
choninic acid assay (QuantiPro BCA;
Sigma), and approximately 20g of pro-
tein was diluted in LDS Sample Buffer
(Invitrogen Life Technologies), heated to
70°C for 10 minutes, and separated on a
4% to 15%NovexNuPAGEBis/Tris gel
(Invitrogen Life Technologies).
Proteins were transferred to a
0.45-m nitrocellulose membrane in
4-morpholinepropanesulfonic acid buf-
fer (MOPS; Invitrogen Life Technolo-
gies), and nonspecific staining was
blocked by incubation overnight with
5% bovine serum albumin (BSA) in
phosphate-buffered saline (PBS) with
0.1% Tween 20 (PBST). Membranes
were probedwith both rabbit antihuman
NK1R antibody (Thermo Scientific,
Lausanne, Switzerland) and mouse anti-
human actin- antibody (Abcam, Cam-
bridge, UK) diluted 1:5000 and 1:1000,
respectively, in 5% BSA in PBST over-
night. Secondary antirabbit (GE Health-
care, Opfikon, Switzerland) and anti-
mouse (Sigma) antibodies conjugated to
horseradish peroxidase were diluted
1:50 000 and 1:120 000, respectively, in
5% BSA in PBST, and immunocomplex
detectionwas performedwith the Super-
Signal West Femto Kit (Pierce; Thermo
Scientific) and a Bio-Rad ChemiDoc
XRS system (Bio-Rad Laboratories
AG, Cressier, Switzerland). Band densi-
tometry was analyzed with Quantity
One analysis software (Bio-Rad Labora-
tories AG). NK1R expression was normalized to actin- expres-
sion, and a positive control reference sample was included on
each gel for comparison across membranes.
Determination of peritoneal fluid cytokine
concentrations
To confirm that material was taken during the proliferative
phase, the progesterone concentrations in the peritoneal fluid
were determined via a RIA (Coat-A-Count, DPC; Buhlmann
Laboratories, Allschwil, Switzerland) with a cutoff value of 27
nmol/L. The protein concentration in the peritoneal fluid was
determined via the BCA assay and the concentration of TNF
was calculated with an ELISA as described previously (3, 4).
Immunofluorescence
EECs and ESCs were seeded onto coverslips, treated with
TNF (0, 10, and 100 ng/mL) for 6 hours, and fixed in 4%
paraformaldehyde in PBS for 10 minutes. Cell membranes were
permeabilized with 2%Triton X-100 in PBS for 15 minutes and
then were incubated with either rabbit antihuman NK1R anti-
body (Thermo Scientific) alone (ESCs) or in combination with a
mouse anti-pan cytokeratin antibody (Abcam) (EECs) diluted
1:200 and 1:250, respectively, in 0.1% BSA in PBS for 1 hour.
After brief washing, cells were incubated with goat antirabbit
IgG DyLight 488 and antimouse IgG DyLight 594 secondary
antibodies (Thermo Scientific) diluted 1:200 in 0.1% BSA in
Figure 1. TACR1 and TACR2 expression in eutopic and ectopic tissue from patients with
endometriosis. In matching ectopic and eutopic endometrial tissue from 21 patients, the
expression of TACR1 (eutopic  0.2848  0.1543 vs ectopic 1.006  0.1563, n  21, P 
.0021) (A) and TACR2 (eutopic  0.3919  0.04818 vs ectopic  3.244  1.153, n  21, P 
.0178) (B) was significantly stronger in the ectopic lesions than in the eutopic tissue. C, When
ectopic lesions were separated based on lesion location, there was a significant variation
between TACR1 expression, as determined by a 1-way ANOVA (F3,39  5.659, P  .0026). A
Bonferroni post hoc test confirmed that TACR1 mRNA expression in peritoneal lesions (1.405 
0.2110, n  8, P  .01) was significantly higher than expression in the eutopic endometrium. No
significant difference was observed, however, between the ovarian lesions (0.6789  0.2361,
n  9, P  .05) or the RVS lesions (0.9425  0.3541, n  4, P  .05). D, In contrast, TACR2
mRNA expression did not show significant variation (F3,39  2.744, P  .0560) between eutopic
endometrium and ectopic lesions on either the peritoneal wall (3.329  1.904, n  8, P  .05),
the ovaries (2.268  1.867, n  9, P  .05), or the RVS (5.273  2.578, n  4, P  .05). All
values are presented as means  SEM. *P  .05, **P  .01.
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PBS. Cells were incubated in 4,6-diamidino-2-phenylindole
(DAPI), 1:5000 for 5 minutes, washed, and mounted onto slides
with ProLong Gold antifade (Invitrogen Life Technologies).
Imageswere capturedwithaZeissAxiovert 40 inverted trans-
mitted-light microscope with a 20 objective and an AxioCam
MRm camera and AxioVision 4.6.3 software (Carl Zeiss, Goet-
tingen, Germany).
Measurement of cell viability
ESCs were plated into 96-well plates at a density of 6000
cells/well and grown for a period of 4 to 6 days until approxi-
mately 80% confluent. Cells were serum starved overnight be-
fore any treatment. Cells were pretreatedwith 100 ng/mLTNF
for 6 hours and treated with 10 nM SP, either in the presence or
absence of 100 nMof L733 606, a specific antagonist forNK1R.
After 24 hours of treatment, cell viability was measured by the
CellTiter 96AQueousOne SolutionCell ProliferationAssay (Pro-
mega) according to the manufacturer’s instructions. All treat-
ments were performed in triplicate for each ESC preparation
isolated from 6 different women. Absorbance values were nor-
malized to a reference sample with no treatment.
Statistical analysis
All statistical analyseswere performedusingGraphPadPrism
(version 5.0 for Mac OS; GraphPad Software Inc., San Diego,
California). The comparison of 2 groups was performed with a
Student t test. For analysis of more than 2 groups, a 1-way
ANOVA was performed with the Bonferroni post hoc test to
compare each pair. To determine whether a significant correla-
tion existed between 2 variables, the Pearson rwas used. For all
statistical tests, significance was set at P  .05.
Results
TACR1 and TACR2 mRNA and NK1R protein are
present and up-regulated in endometriotic lesions
Expression of TACR1 (Figure 1A) was significantly
higher in ectopic tissue than in eutopic tissue. Similarly,
TACR2 expression (Figure 1B) was also significantly
higher in the ectopic tissue than in the matching eutopic
tissue. When ectopic tissue was separated based on lesion
location, a 1-way ANOVA confirmed that a significant
difference existed between TACR1 expression in the eu-
topic tissue and the ectopic tissue thatwas separated based
on location. A Bonferroni post hoc test indicated that ex-
pression of TACR1 was significantly increased in eutopic
tissue from peritoneal lesions but not that from ovarian or
RVS lesions (Figure 1C). No significant difference was
observed in TACR2 expression between eutopic endome-
Figure 2. NK1R protein expression in endometriotic lesions. A,
Western blot analysis with a specific rabbit antihuman NK1R antibody
confirmed that NK1R protein was present in the ectopic endometriotic
lesions. NK1R expression was calculated by normalization within tissue
to actin- and across tissue with a positive control reference sample. B,
Semiquantitative analysis of band densitometry using a 1-way ANOVA
showed a significant difference (F2,11  9.046, P  .0048) among the
3 groups based on lesion location. A Bonferroni post hoc test indicated
that expression of NK1R was significantly stronger in the peritoneal
lesions (269.90  49.46, n  3) than in either the RVS (124.40 
14.01, n  4, P  .05) or ovarian lesions (90.72  24.23, n  7, P 
.01). All values are expressed as means SEM. *P .05, **P .01.
Figure 3. Correlation of NK1R expression with peritoneal fluid TNF. Using the ectopic endometriotic lesions and the matching peritoneal fluid, a
significant positive correlation was observed between the TNF concentration in the peritoneal fluid and both TACR1 mRNA expression (r 
0.5817, n  21, P  .0057) (A) and NK1R protein concentrations (r  0.5845, n  14, P  .0282) (B) in the endometriotic lesions. C, No
significant correlation was observed between TACR2 mRNA and peritoneal fluid TNF concentrations (r  0.2940, n  21, P  .1957). All values
represent means  SEM.
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triumandectopic endometriotic lesions stratifiedby lesion
location (Figure 1D).
The presence ofNK1Rprotein in endometriotic lesions
from all locations was confirmed by the presence of a spe-
cific band of 58 kDa (18) in Western blot analysis (Figure
2A). Semiquantitative analysis of banddensitometryusing
a 1-way ANOVA showed that a significant difference ex-
isted for NK1R expression based on lesion location. A
Bonferroni post hoc test indicated that expression of
NK1R was significantly stronger in the peritoneal lesions
than in either the ovarian orRVS lesions (Figure 2B).Neu-
rokinin 1 receptor (NK2R) protein expression was not
analyzed.
Peritoneal fluid TNF correlates with TACR1 mRNA
and NK1R protein expression in endometriotic
lesions
There was a significant, positive correlation between
peritoneal fluid TNF and TACR1 mRNA (Figure 3A)
andNK1R protein (Figure 3B). No significant association
was observed between peritoneal fluid TNF andTACR2
(Figure 3C). The association be-
tween NK2R and TNF peritoneal
fluid was not analyzed.
TNF treatment of endometrial
stromal cells induces TACR1 but
not TACR2 mRNA expression
A 1-way ANOVA showed no sig-
nificant variation in the TACR1
mRNA expression in EECs (Figure
4A). A similar analysis with ESCs,
however, showeda significantdiffer-
ence in the TACR1 mRNA expres-
sion after TNF treatments. A Bon-
ferroni post hoc test confirmed that a
significant increase in TACR1 ex-
pression occurred after 100 ng/mL
TNF compared with that of the
control (P .05) (Figure 4B). How-
ever, no significant difference was
observed in the TACR2mRNA con-
centration after treatment with ei-
ther 10 or 100 ng/mL in the EECs
(Figure 4C) or ESCs (Figure 4D).
TNF treatment of endometrial
epithelial and stromal cells
induces NK1R expression
Small amounts of NK1R could be
detected by immunofluorescence in
EECs (Figure 5A, green staining and
arrows) without TNF stimulation.
Treatmentwith100ng/mLTNF increased thenumberof
cells positive for NK1R protein (Figure 5B). Pan cytoker-
atin costaining was used to confirm that cells were epi-
thelial (Figure 5, C and D, red staining and arrows). A
merged image of the antirabbit NK1R antibody staining
and the antimouse pan cytokeratin antibody stainingwith
the nuclear DAPI stain confirmed expression of NK1R in
EECs (Figure 5, E and F, blue).
InESCs, therewas somepositive signal forNK1Rstain-
ing under control conditions (Figure 5G, gray arrows).
After treatment with 100 ng/mL TNF, an increase in
NK1R positive immunoreactivity was observed (Figure
5H, gray arrows). This staining was predominantly
cytoplasmic.
SP enhances endometrial stromal cell viability,
whereas L733 606 reduces cell viability
A 24 hours, 10 nM SP treatment of ESCs resulted in a
significant increase in the number of viable ESCs com-
pared with that for no treatment (Figure 6A). To induce
Figure 4. TACR1 and TACR2 mRNA expression in epithelial and stromal cells after TNF
treatment. A, 1-way ANOVA comparing the control (0.6875  0.1465, n  4), 10 ng/mL TNF
(1.1400  0.2567, n  4), and 100 ng/mL TNF (1.590  0.2598, n  4) treatments showed no
significant variation in the TACR1 mRNA expression in EECs (F2,9  3.944, P  .0589). B, Similar
analysis showed a significant difference in the TACR1 mRNA expression in ESCs (F2,14  5.850,
P  .0142), between the control (0.6967  0.1831, n  6), 10 ng/mL TNF (0.9160  0.1372,
n  5), and 100 ng/mL TNF (1.403  0.1273) conditions. A Bonferroni post hoc test confirmed
that a significant increase in TACR1 expression occurred after 100 ng/mL TNF compared with
that in the control (P  .05). No significant difference was observed in TACR2 mRNA expression
in either EECs (F2,9  1.327, P  .3126; control  1.2030  0.1644, n  4; 10 ng/mL TNF 
0.9075  0.1111, n  4; 100 ng/mL TNF  0.9925  0.1129, n  4) (C) or ESCs (F2,15 
2.200, P  .1452, control  1.1430  0.1112, n  6; 10 ng/mL TNF  0.9767  0.0407, n 
6; 100 ng/mL TNF  0.9300  0.0560, n  6) (D) at both concentrations tested. All values
represent means  SEM. *P  .05, **P  .01.
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NK1R expression, ESCs were pretreated with 100 ng/mL
TNF before treatment with either 10 nM SP alone, with
100 nML733 606 alone, or with a combination of SP and
L733 606 together. A 1-way ANOVA showed that there
was a significant difference between the means of the 5
treatment groups. A Bonferroni post hoc comparison be-
tween all 5 groups indicated that treatment with 100 nM
L733 606 significantly reduced the number of viable cells
compared with either TNF treat-
ment alone or TNF treatment in
combinationwith 10 nMSP.No sig-
nificant difference was observed be-
tween the remaining pairs.
Discussion
The presence of the tachykinin re-
ceptors in endometrial tissue has not
been reportedpreviously.The results
of this study show that both TACR1
and TACR2, genes that encode
tachykinin receptors, are expressed
in eutopic endometrial tissue and are
significantly up-regulated in endo-
metriotic lesions derived from the
same women. The expression of
both the TACR1 gene and the pro-
tein it encodes,NK1R,was related to
peritoneal fluid TNF concentra-
tions, and in vitro experiments con-
firmed that TNF induced both
TACR1 and NK1R in eutopic ESCs.
Exposure to SP also increased the vi-
ability of ESCs, whereas specifically
blocking NK1R with an antagonist
reduced the viability of ESCs that
had previously been exposed to
TNF. This induction of NK1R in
endometriotic tissue by the inflam-
matory microenvironment and the
response to SP and NK1R antago-
nists may represent the potential for
neurogenic control over the mainte-
nance of ectopic lesions.
Based on the theory of retrograde
menstruation (19), ectopic lesions
arederived fromrefluxed eutopic tis-
sue and pathogenic changes in this
tissue give rise to the ensuing lesions.
In this study, we used matched eu-
topic and ectopic endometrial tissue
from the same women and observed
an increase in NK1R expression in the endometriotic le-
sion. By analyzing matched tissue, these results suggest
that adirect inductionofNK1Roccursonlyonce the tissue
became abnormal, and by using peritoneal fluid samples,
also from the same women, we established that exposure
to the inflammatorymicroenvironment and, in particular,
to TNF, was important for this induction. Furthermore,
for the in vitro studies we used cells isolated from eutopic
Figure 5. NK1R expression in endometrial epithelial and stromal cells after TNF treatment.
EECs (A–F) and ESCs (G and H) were treated for 6 hours as either control (A, C, E, and G) or with
100 ng/mL TNF (B, D, F, and H). A–D, Double staining of endometrial epithelial cells with a
rabbit anti-NK1R antibody followed by an antirabbit DyLight 488 antibody (green; A and B) and a
mouse anticytokeratin antibody followed by an antimouse DyLight 594 antibody (red; C and D).
E and F, Merged image of NK1R and cytokeratin staining with a DAPI nuclear (blue) stain. G and
H, Single staining of ESCs with rabbit anti-NK1R antibody followed by an antirabbit DyLight 488
antibody (green) and a nuclear DAPI stain. White arrows indicate cells costained for both NK1R
and cytokeratin (A–F), and gray arrows indicate regions of positive NK1R cytoplasmic staining (G
and H).
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endometrial tissue and confirmed that TNF can signifi-
cantly increaseNK1R expression in these cells. Therefore,
the inflammatory microenvironment may induce an up-
regulation of NK1R expression in refluxed eutopic cells,
and this may contribute to a pathogenic transformation.
Because lesions in the peritoneum, ovary, and RVS
could be considered distinct but related conditions (20),
we also compared TACR1 and NK1R expression among
lesions from different locations. At the RNA level, we
found that only lesions in the peritoneal wall had signif-
icantly increased expression above that of the eutopic tis-
sue, whereas at the protein level NK1R expression in the
peritoneumwas significantly higher than that observed in
either theovarianorRVS lesions. Peritoneal lesions are the
most likely to have significant exposure to peritoneal fluid
and the inflammatory mediators contained within. In-
creased exposure to inflammation might explain the ele-
vated expression of NK1R in these lesions and suggests
that these lesions in particular could be more susceptible
to neurogenic control.
An increase in NK1R expression has been noted pre-
viously in other inflammatory diseases, and TNF, a cy-
tokine related to endometriosis progression (21), was an
important mediator of this increase. There was a signifi-
cant increase in NK1R expression in colonic mucosal bi-
opsy samples frompatientswith irritable bowel syndrome
(22), whichwas induced in vitro by a
cocktail of TH-1 cytokines including
TNF (23). A significantly increased
NK1R expression was observed in
Clostridium difficile–induced en-
terocolitis (24) and interstitial cysti-
tis (25). NK1R expression was also
induced in rheumatoid arthritis sy-
noviocytes (26) by TNF (13). Both
IL-1 and TNF can induce NK1R
inmonocytes (14). TNF concentra-
tions are significantly increased in
the peritoneal fluid of women with
endometriosis (27–29) and given
that the average delay in diagnosis
for endometriosis is between 3 and
11 years after the onset of symptoms
(30), the ectopic tissue could be ex-
posed to high TNF levels for a con-
siderable periodof time.A long-term
exposure to even small concentra-
tions of TNF could be sufficient to
induce NK1R expression in ectopic
lesions.
A significant induction of the
TACR2 gene in ectopic tissue was
also observed, although as opposed
to TACR1, this was not specific to lesions from any par-
ticular region. The role ofNK2R in endometriotic tissue is
not clear but deserves further attention. Previous evidence
indicates that NK2R can also be up-regulated by TNF in
synoviocytes (13), although in endometrial tissue another
substance is likely to be responsible because it was not
correlatedwith peritoneal fluid TNF norwas the expres-
sion up-regulated in primary cells after TNF treatment in
this study. TACR3 showed very little or no expression in
both the eutopic and ectopic endometrial tissue and was
not investigated further.
Both the RNA results and the immunofluorescent im-
ages, although not quantitative, suggest that NK1R in-
duction by TNF occurred predominantly in the stromal
cells. Notably, however, treatment of ESCs with SP even
without any prior in vitro exposure to TNF still signif-
icantly increased the viability of these cells. The RNA and
protein analysis showed that some basal expression, al-
though low, exists in both the EECs and ESCs, which
suggests that even low basal expression of NK1R in eu-
topic tissue may be sufficient for the maintenance of these
cells when exposed to SP. Many previous studies have
shown thatwomenwith endometriosis have variable gene
expression in their eutopic endometrium that may predis-
pose them to development of endometriosis or infertility
Figure 6. Proliferation of endometrial stromal cells after treatment with SP. A, Treatment of
ESCs with 10 nM SP resulted in a significant increase in the number of viable cells compared with
no treatment after a 24-hour period (control  96.59  1.66%, n  6 vs 10 nM SP  103.40 
2.45%, n  6; P  .0438). B, When cells were pretreated with 100 ng/mL TNF a 1-way ANOVA
test found a significant difference (F4,25  4.917, P  .0046) between the 5 groups, which
included control (96.59  1.66%, n  6), 100 ng/mL TNF only (105.50  2.94%, n  6), 100
ng/mL TNF and 10 nM SP (107.40  3.25%, n  6), 10 nM SP and 100 nM L733 606 (95.07 
2.59%, n  6), or 100 nM L733 606 alone (87.42  6.25%, n  6). A Bonferroni post hoc
comparison indicated a significant reduction in the number of viable cells that occurred when
ESCs were treated with 100 nM L733 606 alone compared with either the 100 ng/mL TNF
group (P  .05) or the 100 ng/mL TNF and 10 nM SP group (P  .01). All values are reported as
means  SEM. *P  .05, **P  .01.
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through implantation failure (31). Because the ESCs used
in this study were isolated only from women with con-
firmed cases of endometriosis, it is possible that a suscep-
tibility to SP may be specific to the eutopic endometrium
of women with endometriosis. Recent studies have sug-
gested that nerve fibers are found in the eutopic endome-
trium of women with endometriosis (32, 33). Because of
thesenerve fibers,womenwith endometriosismayhaveSP
and SP-mediated mechanisms already functioning within
the eutopic endometrium with the potential for neuro-
genic control within this tissue. A comparison of TACR1
andNK1R expression and the ability of SP to support cell
viability in the eutopic endometriumbetweenwomenwith
and without endometriosis is an interesting avenue for
future studies.
In addition, the inclusion of a specific antagonist for
NK1R, L733 606, provided strong evidence that blocking
of the NK1R-SP pathway in cells that have been exposed
to TNF can reduce the viability of ESCs. NK1R-SP bind-
ing has previously been shown to contribute to cell via-
bility by inducing proliferation or preventing apoptosis in
both normal and pathological cells such as epithelial cells
of the intestines (34), lymphocytes (35), and glioblastoma
cells (36). Therefore, it may also represent a possible av-
enue to reduce cell viability and the size of endometriotic
lesions by using specificNK1Rantagonists such as aprepi-
tant, although further studies will be needed to confirm
this.
The combination of induced expression of NK1R by
exposure to an inflammatory environment, the ability of
SP to support ESC viability, and the ability of specific
NK1R antagonists to reduce it suggests that NK1R may
contribute to endometriotic lesion maintenance. In addi-
tion, it is an intriguing possibility that the pain response
itself may have a role in lesion maintenance. SP is released
from sensory nerve fibers, and this secretion can be up-
regulated in response to nerve damage (37) and inflam-
mation (38). Nerve fibers proximal to endometriotic le-
sions can be activated both physically, by infiltration of
the lesion (6, 39), or chemically, by pain-associated pros-
taglandins (40, 41). The activation of these nerve fibers
could not only send an afferent nerve signal but also re-
lease SP locally. Locally secreted SP could bind to NK1R
and assist in maintaining cell viability of the ectopic le-
sions. A similarmechanismhas been postulated for gastric
cancer (42). In addition, because evidence is beginning to
show that pain itself can become independent of the dis-
ease through activation of the central and peripheral ner-
vous system, researchers have suggested that the focus of
endometriosis research should be more on pain rather
than on morphological changes (43), potentially leading
to clinical treatments that focus on chronic pain manage-
ment. The expression of NK1R and the ability of tachy-
kinins to activate it may serve as a link between the mor-
phology of the disease and the production of sustained
painful symptoms.
The neuroimmune axis is a bidirectional pathway of
intersystem communication. Endometriotic lesions are
characterized by the growth of ectopic endometrial tissue.
They also have neurotrophic properties (44) and are fre-
quently found to be innervated. The results of this study
suggest that ectopic endometrial tissue expresses NK1R
and that this receptor can be induced by an inflammatory
microenvironment. The presence of this receptor in an
innervated environment may allow a positive feedback
loop to exist between the pain-generating aspects of the
disease and the maintenance of the ectopic tissue.
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